NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 230 filers reported holding NOVOCURE LTD in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $19,441,000 | -76.1% | 258,937 | -63.0% | 0.90% | -66.4% |
| Q3 2021 | $81,319,000 | -47.6% | 700,000 | 0.0% | 2.68% | -39.3% |
| Q2 2021 | $155,274,000 | +134.9% | 700,000 | +40.0% | 4.42% | +139.1% |
| Q1 2021 | $66,090,000 | -49.1% | 500,000 | -33.3% | 1.85% | -49.6% |
| Q4 2020 | $129,780,000 | -12.0% | 750,000 | -43.4% | 3.66% | -51.2% |
| Q3 2020 | $147,486,000 | +46.3% | 1,325,000 | -22.1% | 7.50% | +25.6% |
| Q2 2020 | $100,810,000 | +10.9% | 1,700,000 | +25.9% | 5.98% | +39.0% |
| Q1 2020 | $90,909,000 | -20.1% | 1,350,000 | 0.0% | 4.30% | +10.8% |
| Q4 2019 | $113,765,000 | +52.1% | 1,350,000 | +35.0% | 3.88% | +39.9% |
| Q3 2019 | $74,780,000 | -21.2% | 1,000,000 | -33.3% | 2.77% | -10.0% |
| Q2 2019 | $94,845,000 | +12.5% | 1,500,000 | -14.3% | 3.08% | -2.4% |
| Q1 2019 | $84,298,000 | +17.1% | 1,750,000 | -18.6% | 3.16% | +4.8% |
| Q4 2018 | $71,982,000 | +66.5% | 2,150,000 | +160.6% | 3.01% | +122.3% |
| Q3 2018 | $43,225,000 | – | 824,911 | – | 1.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 470,884 | $27,923,000 | 10.09% |
| Darsana Capital Partners LP | 1,700,000 | $100,810,000 | 5.98% |
| HARTLINE INVESTMENT CORP/ | 336,617 | $19,961,000 | 4.18% |
| Rhenman & Partners Asset Management AB | 375,000 | $22,238,000 | 2.40% |
| MORGAN JESS S & CO INC | 35,942 | $2,131,000 | 2.31% |
| Soleus Capital Management, L.P. | 56,397 | $3,344,000 | 1.91% |
| Bullseye Asset Management LLC | 45,161 | $2,678,000 | 1.43% |
| Taylor Frigon Capital Management LLC | 46,304 | $2,746,000 | 1.36% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $593,000 | 1.09% |
| Redwood Investments, LLC | 192,986 | $11,444,000 | 1.01% |